Smith & Nephew SNATS, Inc. (SNN) - What Are Analysts Saying About This Stock?

Key Points

• Analysts have a consensus “Hold” rating on Smith & Nephew SNATS, with nine holds, one sell, and one buy; the average 12-month price target is $31.91.
• Institutional investors have made significant moves into the stock, including new positions by BlackRock, Bank of America, Bank of New York Mellon, and Caisse de dépôt et placement du Québec; institutions and hedge funds own 25.64% of shares.
• SNN shares opened at $29.05, within a 52-week range of $26.12 to $37.51. The company also declared a $0.312-per-share dividend payable November 6 to shareholders of record October 2.

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) have been assigned a consensus rating of "Hold" from the eleven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $31.91.

SNN has been the topic of several recent research reports. Weiss Ratings downgraded Smith & Nephew SNATS from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, September 24th. Wall Street Zen upgraded Smith & Nephew SNATS from a "hold" rating to a "buy" rating in a research report on Sunday, September 13th. Berenberg Bank set a $33.88 target price on shares of Smith & Nephew SNATS in a research note on Friday, September 11th. Barclays downgraded shares of Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded shares of Smith & Nephew SNATS from a "strong sell" rating to a "hold" rating in a report on Tuesday, September 8th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SNN. BlackRock Inc. acquired a new stake in Smith & Nephew SNATS during the second quarter valued at approximately $505,323,000. River Road Asset Management LLC raised its stake in shares of Smith & Nephew SNATS by 13.8% in the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider's stock worth $103,996,000 after buying an additional 384,926 shares in the last quarter. Bank of America Corp DE bought a new position in Smith & Nephew SNATS during the second quarter valued at about $97,223,000. Bank of New York Mellon Corp acquired a new position in Smith & Nephew SNATS during the second quarter worth about $89,325,000. Finally, Caisse de depot et placement du Quebec acquired a new position in Smith & Nephew SNATS during the second quarter worth about $64,186,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock opened at $29.05 on Friday. The stock's 50-day moving average is $28.26 and its two-hundred day moving average is $30.01. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a 1 year low of $26.12 and a 1 year high of $37.51.

Smith & Nephew SNATS Announces Dividend

The company also recently declared a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.3120 per share. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 236.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in Watford, England. Founded in 1856 by pharmacist Thomas James Smith in Hull, the company has grown from a pharmacy business into a provider of surgical and wound-care products for healthcare professionals and patients.

The company operates through three principal areas: Orthopaedics, Sports Medicine, and Advanced Wound Management. Its products include joint-replacement systems, trauma and extremity devices, arthroscopy equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products used to support healing and tissue recovery.

Smith & Nephew serves hospitals, clinics, surgeons, and patients in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific, and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.